Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Critical differences in drug metabolic properties of human hepatic cellular models, including primary human hepatocytes, stem cell derived hepatocytes, and hepatoma cell lines.

Kvist AJ, Kanebratt KP, Walentinsson A, Palmgren H, O'Hara M, Björkbom A, Andersson LC, Ahlqvist M, Andersson TB.

Biochem Pharmacol. 2018 Sep;155:124-140. doi: 10.1016/j.bcp.2018.06.026. Epub 2018 Jun 25.

PMID:
29953844
2.

Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL).

Hjelmesæth J, Åsberg A, Andersson S, Sandbu R, Robertsen I, Johnson LK, Angeles PC, Hertel JK, Skovlund E, Heijer M, Ek AL, Krogstad V, Karlsen TI, Christensen H, Andersson TB, Karlsson C.

BMJ Open. 2018 May 29;8(5):e021878. doi: 10.1136/bmjopen-2018-021878.

3.

Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s.

Lindmark B, Lundahl A, Kanebratt KP, Andersson TB, Isin EM.

Br J Pharmacol. 2018 Jun;175(11):2116-2129. doi: 10.1111/bph.14203. Epub 2018 Apr 19.

PMID:
29574682
4.

Cytochrome P450 Induction and Xeno-Sensing Receptors Pregnane X Receptor, Constitutive Androstane Receptor, Aryl Hydrocarbon Receptor and Peroxisome Proliferator-Activated Receptor α at the Crossroads of Toxicokinetics and Toxicodynamics.

Hakkola J, Bernasconi C, Coecke S, Richert L, Andersson TB, Pelkonen O.

Basic Clin Pharmacol Toxicol. 2018 Sep;123 Suppl 5:42-50. doi: 10.1111/bcpt.13004. Epub 2018 Apr 29. Review.

PMID:
29527807
5.

Publisher Correction: Functional coupling of human pancreatic islets and liver spheroids on-a-chip: Towards a novel human ex vivo type 2 diabetes model.

Bauer S, Wennberg Huldt C, Kanebratt KP, Durieux I, Gunne D, Andersson S, Ewart L, Haynes WG, Maschmeyer I, Winter A, Ämmälä C, Marx U, Andersson TB.

Sci Rep. 2018 Jan 23;8(1):1672. doi: 10.1038/s41598-018-20340-1.

6.

Functional coupling of human pancreatic islets and liver spheroids on-a-chip: Towards a novel human ex vivo type 2 diabetes model.

Bauer S, Wennberg Huldt C, Kanebratt KP, Durieux I, Gunne D, Andersson S, Ewart L, Haynes WG, Maschmeyer I, Winter A, Ämmälä C, Marx U, Andersson TB.

Sci Rep. 2017 Nov 6;7(1):14620. doi: 10.1038/s41598-017-14815-w. Erratum in: Sci Rep. 2018 Jan 23;8(1):1672.

7.

Variability in Mass Spectrometry-based Quantification of Clinically Relevant Drug Transporters and Drug Metabolizing Enzymes.

Wegler C, Gaugaz FZ, Andersson TB, Wiśniewski JR, Busch D, Gröer C, Oswald S, Norén A, Weiss F, Hammer HS, Joos TO, Poetz O, Achour B, Rostami-Hodjegan A, van de Steeg E, Wortelboer HM, Artursson P.

Mol Pharm. 2017 Sep 5;14(9):3142-3151. doi: 10.1021/acs.molpharmaceut.7b00364. Epub 2017 Aug 16.

8.

Comparative transcriptomics of hepatic differentiation of human pluripotent stem cells and adult human liver tissue.

Ghosheh N, Küppers-Munther B, Asplund A, Edsbagge J, Ulfenborg B, Andersson TB, Björquist P, Andersson CX, Carén H, Simonsson S, Sartipy P, Synnergren J.

Physiol Genomics. 2017 Aug 1;49(8):430-446. doi: 10.1152/physiolgenomics.00007.2017. Epub 2017 Jul 10.

9.

Evolution of Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates.

Andersson TB.

Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):234-238. doi: 10.1111/bcpt.12804. Epub 2017 Jul 3. Review.

10.

Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury.

Bell CC, Lauschke VM, Vorrink SU, Palmgren H, Duffin R, Andersson TB, Ingelman-Sundberg M.

Drug Metab Dispos. 2017 Apr;45(4):419-429. doi: 10.1124/dmd.116.074369. Epub 2017 Jan 30.

11.

Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach.

Jones BC, Rollison H, Johansson S, Kanebratt KP, Lambert C, Vishwanathan K, Andersson TB.

Drug Metab Dispos. 2017 Jan;45(1):35-41. Epub 2016 Oct 24. Review.

12.

Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation.

Lauschke VM, Vorrink SU, Moro SM, Rezayee F, Nordling Å, Hendriks DF, Bell CC, Sison-Young R, Park BK, Goldring CE, Ellis E, Johansson I, Mkrtchian S, Andersson TB, Ingelman-Sundberg M.

Hepatology. 2016 Nov;64(5):1743-1756. doi: 10.1002/hep.28780. Epub 2016 Sep 30.

PMID:
27532775
13.

Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates.

Lauschke VM, Hendriks DF, Bell CC, Andersson TB, Ingelman-Sundberg M.

Chem Res Toxicol. 2016 Dec 19;29(12):1936-1955. Epub 2016 Sep 23. Review.

PMID:
27661221
14.

CYP3A Specifically Catalyzes 1β-Hydroxylation of Deoxycholic Acid: Characterization and Enzymatic Synthesis of a Potential Novel Urinary Biomarker for CYP3A Activity.

Hayes MA, Li XQ, Grönberg G, Diczfalusy U, Andersson TB.

Drug Metab Dispos. 2016 Sep;44(9):1480-9. doi: 10.1124/dmd.116.070805. Epub 2016 Jul 11.

15.

Bile canaliculi formation and biliary transport in 3D sandwich-cultured hepatocytes in dependence of the extracellular matrix composition.

Deharde D, Schneider C, Hiller T, Fischer N, Kegel V, Lübberstedt M, Freyer N, Hengstler JG, Andersson TB, Seehofer D, Pratschke J, Zeilinger K, Damm G.

Arch Toxicol. 2016 Oct;90(10):2497-511. doi: 10.1007/s00204-016-1758-z. Epub 2016 Jun 21.

PMID:
27325308
16.

Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing.

Marx U, Andersson TB, Bahinski A, Beilmann M, Beken S, Cassee FR, Cirit M, Daneshian M, Fitzpatrick S, Frey O, Gaertner C, Giese C, Griffith L, Hartung T, Heringa MB, Hoeng J, de Jong WH, Kojima H, Kuehnl J, Leist M, Luch A, Maschmeyer I, Sakharov D, Sips AJ, Steger-Hartmann T, Tagle DA, Tonevitsky A, Tralau T, Tsyb S, van de Stolpe A, Vandebriel R, Vulto P, Wang J, Wiest J, Rodenburg M, Roth A.

ALTEX. 2016;33(3):272-321. doi: 10.14573/altex.1603161. Epub 2016 May 15. Review.

17.

Highly Synchronized Expression of Lineage-Specific Genes during In Vitro Hepatic Differentiation of Human Pluripotent Stem Cell Lines.

Ghosheh N, Olsson B, Edsbagge J, Küppers-Munther B, Van Giezen M, Asplund A, Andersson TB, Björquist P, Carén H, Simonsson S, Sartipy P, Synnergren J.

Stem Cells Int. 2016;2016:8648356. doi: 10.1155/2016/8648356. Epub 2016 Feb 1.

18.

HepaRG cells as human-relevant in vitro model to study the effects of inflammatory stimuli on cytochrome P450 isoenzymes.

Rubin K, Janefeldt A, Andersson L, Berke Z, Grime K, Andersson TB.

Drug Metab Dispos. 2015 Jan;43(1):119-25. doi: 10.1124/dmd.114.059246. Epub 2014 Nov 4.

19.

Long-term chronic toxicity testing using human pluripotent stem cell-derived hepatocytes.

Holmgren G, Sjögren AK, Barragan I, Sabirsh A, Sartipy P, Synnergren J, Björquist P, Ingelman-Sundberg M, Andersson TB, Edsbagge J.

Drug Metab Dispos. 2014 Sep;42(9):1401-6. doi: 10.1124/dmd.114.059154. Epub 2014 Jun 30.

20.

Critical differences in toxicity mechanisms in induced pluripotent stem cell-derived hepatocytes, hepatic cell lines and primary hepatocytes.

Sjogren AK, Liljevald M, Glinghammar B, Sagemark J, Li XQ, Jonebring A, Cotgreave I, Brolén G, Andersson TB.

Arch Toxicol. 2014 Jul;88(7):1427-37. doi: 10.1007/s00204-014-1265-z. Epub 2014 Jun 10.

PMID:
24912781
21.

Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.

Björkhem-Bergman L, Bäckström T, Nylén H, Rönquist-Nii Y, Bredberg E, Andersson TB, Bertilsson L, Diczfalusy U.

Drug Metab Pharmacokinet. 2014;29(4):352-5. Epub 2014 Feb 11.

22.

The impact of solute carrier (SLC) drug uptake transporter loss in human and rat cryopreserved hepatocytes on clearance predictions.

Lundquist P, Lööf J, Sohlenius-Sternbeck AK, Floby E, Johansson J, Bylund J, Hoogstraate J, Afzelius L, Andersson TB.

Drug Metab Dispos. 2014 Mar;42(3):469-80. doi: 10.1124/dmd.113.054676. Epub 2014 Jan 6.

23.

Functional ATP-binding cassette drug efflux transporters in isolated human and rat hepatocytes significantly affect assessment of drug disposition.

Lundquist P, Englund G, Skogastierna C, Lööf J, Johansson J, Hoogstraate J, Afzelius L, Andersson TB.

Drug Metab Dispos. 2014 Mar;42(3):448-58. doi: 10.1124/dmd.113.054528. Epub 2014 Jan 6.

24.

Prediction of in vivo rat biliary drug clearance from an in vitro hepatocyte efflux model.

Lundquist P, Lööf J, Fagerholm U, Sjögren I, Johansson J, Briem S, Hoogstraate J, Afzelius L, Andersson TB.

Drug Metab Dispos. 2014 Mar;42(3):459-68. doi: 10.1124/dmd.113.054155. Epub 2014 Jan 6.

25.

Cytochrome p450 inhibitory properties of common efflux transporter inhibitors.

Englund G, Lundquist P, Skogastierna C, Johansson J, Hoogstraate J, Afzelius L, Andersson TB, Projean D.

Drug Metab Dispos. 2014 Mar;42(3):441-7. doi: 10.1124/dmd.113.054932. Epub 2014 Jan 6.

26.

Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells.

Ulvestad M, Nordell P, Asplund A, Rehnström M, Jacobsson S, Holmgren G, Davidson L, Brolén G, Edsbagge J, Björquist P, Küppers-Munther B, Andersson TB.

Biochem Pharmacol. 2013 Sep 1;86(5):691-702. doi: 10.1016/j.bcp.2013.06.029. Epub 2013 Jul 12.

PMID:
23856292
27.

A P-gp vesicular transport inhibition assay - optimization and validation for drug-drug interaction testing.

Herédi-Szabó K, Palm JE, Andersson TB, Pál Á, Méhn D, Fekete Z, Beéry E, Jakab KT, Jani M, Krajcsi P.

Eur J Pharm Sci. 2013 Jul 16;49(4):773-81. doi: 10.1016/j.ejps.2013.04.032. Epub 2013 May 15.

PMID:
23684934
28.

Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin.

Björkhem-Bergman L, Bäckström T, Nylén H, Rönquist-Nii Y, Bredberg E, Andersson TB, Bertilsson L, Diczfalusy U.

Drug Metab Dispos. 2013 Aug;41(8):1488-93. doi: 10.1124/dmd.113.052316. Epub 2013 May 14.

29.

Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.

Ulvestad M, Skottheim IB, Jakobsen GS, Bremer S, Molden E, Asberg A, Hjelmesæth J, Andersson TB, Sandbu R, Christensen H.

Clin Pharmacol Ther. 2013 Mar;93(3):275-82. doi: 10.1038/clpt.2012.261. Epub 2012 Dec 27. Erratum in: Clin Pharmacol Ther. 2015 Apr;97(4):428.

PMID:
23361102
30.

Serum-free culture of primary human hepatocytes in a miniaturized hollow-fibre membrane bioreactor for pharmacological in vitro studies.

Lübberstedt M, Müller-Vieira U, Biemel KM, Darnell M, Hoffmann SA, Knöspel F, Wönne EC, Knobeloch D, Nüssler AK, Gerlach JC, Andersson TB, Zeilinger K.

J Tissue Eng Regen Med. 2015 Sep;9(9):1017-26. doi: 10.1002/term.1652. Epub 2012 Nov 20.

PMID:
23165723
31.

Evaluation of organic anion-transporting polypeptide 1B1 and CYP3A4 activities in primary human hepatocytes and HepaRG cells cultured in a dynamic three-dimensional bioreactor system.

Ulvestad M, Darnell M, Molden E, Ellis E, Åsberg A, Andersson TB.

J Pharmacol Exp Ther. 2012 Oct;343(1):145-56. doi: 10.1124/jpet.112.195750. Epub 2012 Jul 12.

32.

In vitro evaluation of major in vivo drug metabolic pathways using primary human hepatocytes and HepaRG cells in suspension and a dynamic three-dimensional bioreactor system.

Darnell M, Ulvestad M, Ellis E, Weidolf L, Andersson TB.

J Pharmacol Exp Ther. 2012 Oct;343(1):134-44. doi: 10.1124/jpet.112.195834. Epub 2012 Jul 9.

33.

Analysis of drug metabolism activities in a miniaturized liver cell bioreactor for use in pharmacological studies.

Hoffmann SA, Müller-Vieira U, Biemel K, Knobeloch D, Heydel S, Lübberstedt M, Nüssler AK, Andersson TB, Gerlach JC, Zeilinger K.

Biotechnol Bioeng. 2012 Dec;109(12):3172-81. doi: 10.1002/bit.24573. Epub 2012 Jun 27.

PMID:
22688505
34.

An ex vivo perfusion system emulating in vivo conditions in noncirrhotic and cirrhotic human liver.

Schreiter T, Marquitan G, Darnell M, Sowa JP, Bröcker-Preuss M, Andersson TB, Baba HA, Furch M, Arteel GE, Mathé Z, Treckmann J, Gerken G, Gieseler RK, Canbay A.

J Pharmacol Exp Ther. 2012 Sep;342(3):730-41. doi: 10.1124/jpet.112.194167. Epub 2012 Jun 6.

35.

The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human.

Andersson TB, Kanebratt KP, Kenna JG.

Expert Opin Drug Metab Toxicol. 2012 Jul;8(7):909-20. doi: 10.1517/17425255.2012.685159. Epub 2012 May 8. Review.

PMID:
22568886
36.

Amidoxime reductase system containing cytochrome b5 type B (CYB5B) and MOSC2 is of importance for lipid synthesis in adipocyte mitochondria.

Neve EP, Nordling A, Andersson TB, Hellman U, Diczfalusy U, Johansson I, Ingelman-Sundberg M.

J Biol Chem. 2012 Feb 24;287(9):6307-17. doi: 10.1074/jbc.M111.328237. Epub 2011 Dec 27.

37.

Development of a highly sensitive method using liquid chromatography-multiple reaction monitoring to quantify membrane P-glycoprotein in biological matrices and relationship to transport function.

Miliotis T, Ali L, Palm JE, Lundqvist AJ, Ahnoff M, Andersson TB, Hilgendorf C.

Drug Metab Dispos. 2011 Dec;39(12):2440-9. doi: 10.1124/dmd.111.040774. Epub 2011 Sep 23.

38.

OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture.

Ulvestad M, Björquist P, Molden E, Asberg A, Andersson TB.

Biochem Pharmacol. 2011 Nov 1;82(9):1219-26. doi: 10.1016/j.bcp.2011.07.076. Epub 2011 Jul 20. Erratum in: Biochem Pharmacol. 2012 Oct 15;84(8):1103.

PMID:
21787759
39.

Toward preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitro models derived from human embryonic stem cells and human cell lines - a report on the Vitrocellomics EU-project.

Mandenius CF, Andersson TB, Alves PM, Batzl-Hartmann C, Björquist P, Carrondo MJ, Chesne C, Coecke S, Edsbagge J, Fredriksson JM, Gerlach JC, Heinzle E, Ingelman-Sundberg M, Johansson I, Küppers-Munther B, Müller-Vieira U, Noor F, Zeilinger K.

Altern Lab Anim. 2011 May;39(2):147-71.

PMID:
21639679
40.

Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor.

Darnell M, Schreiter T, Zeilinger K, Urbaniak T, Söderdahl T, Rossberg I, Dillnér B, Berg AL, Gerlach JC, Andersson TB.

Drug Metab Dispos. 2011 Jul;39(7):1131-8. doi: 10.1124/dmd.110.037721. Epub 2011 Mar 24.

41.

Scaling down of a clinical three-dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies.

Zeilinger K, Schreiter T, Darnell M, Söderdahl T, Lübberstedt M, Dillner B, Knobeloch D, Nüssler AK, Gerlach JC, Andersson TB.

Tissue Eng Part C Methods. 2011 May;17(5):549-56. doi: 10.1089/ten.TEC.2010.0580. Epub 2011 Feb 16.

PMID:
21210724
42.

In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics.

Zhou D, Andersson TB, Grimm SW.

Drug Metab Dispos. 2011 Apr;39(4):703-10. doi: 10.1124/dmd.110.037143. Epub 2010 Dec 22.

43.

The application of HepRG cells in evaluation of cytochrome P450 induction properties of drug compounds.

Andersson TB.

Methods Mol Biol. 2010;640:375-87. doi: 10.1007/978-1-60761-688-7_20.

PMID:
20645063
44.

Hepatic disposition of ximelagatran and its metabolites in pig; prediction of the impact of membrane transporters through a simple disposition model.

Sjögren E, Bredberg U, Allard E, Arvidsson B, Bergquist J, Andersson TB, Lennernäs H.

Pharm Res. 2010 Apr;27(4):597-607. doi: 10.1007/s11095-009-0016-y. Epub 2010 Feb 6.

PMID:
20140637
45.

High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.

Karlsson JE, Heddle C, Rozkov A, Rotticci-Mulder J, Tuvesson O, Hilgendorf C, Andersson TB.

Drug Metab Dispos. 2010 Apr;38(4):705-14. doi: 10.1124/dmd.109.028886. Epub 2010 Jan 13.

46.

Investigation of the involvement of P-glycoprotein and multidrug resistance-associated protein 2 in the efflux of ximelagatran and its metabolites by using short hairpin RNA knockdown in Caco-2 cells.

Darnell M, Karlsson JE, Owen A, Hidalgo IJ, Li J, Zhang W, Andersson TB.

Drug Metab Dispos. 2010 Mar;38(3):491-7. doi: 10.1124/dmd.109.029967. Epub 2009 Dec 18.

47.

Drug-induced liver injury in humans: the case of ximelagatran.

Keisu M, Andersson TB.

Handb Exp Pharmacol. 2010;(196):407-18. doi: 10.1007/978-3-642-00663-0_13. Review.

PMID:
20020269
48.

Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage.

Brolén G, Sivertsson L, Björquist P, Eriksson G, Ek M, Semb H, Johansson I, Andersson TB, Ingelman-Sundberg M, Heins N.

J Biotechnol. 2010 Feb 1;145(3):284-94. doi: 10.1016/j.jbiotec.2009.11.007. Epub 2009 Nov 20.

PMID:
19932139
49.

Ximelagatran increases membrane fluidity and changes membrane lipid composition in primary human hepatocytes.

Sergent O, Ekroos K, Lefeuvre-Orfila L, Rissel M, Forsberg GB, Oscarsson J, Andersson TB, Lagadic-Gossmann D.

Toxicol In Vitro. 2009 Oct;23(7):1305-10. doi: 10.1016/j.tiv.2009.07.019. Epub 2009 Jul 16.

PMID:
19616086
50.

4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin.

Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Böttiger Y, Bertilsson L.

Br J Clin Pharmacol. 2009 Jan;67(1):38-43. doi: 10.1111/j.1365-2125.2008.03309.x. Epub 2008 Nov 6.

Supplemental Content

Loading ...
Support Center